Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Algert Global LLC

Algert Global LLC cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 49.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,763 shares of the company's stock after selling 41,270 shares during the quarter. Algert Global LLC owned 0.06% of Replimune Group worth $469,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in REPL. Millennium Management LLC increased its position in shares of Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the period. Acadian Asset Management LLC increased its holdings in Replimune Group by 63.2% during the 2nd quarter. Acadian Asset Management LLC now owns 185,516 shares of the company's stock worth $1,668,000 after purchasing an additional 71,867 shares during the period. Cubist Systematic Strategies LLC raised its position in Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock valued at $650,000 after purchasing an additional 53,313 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock valued at $5,313,000 after buying an additional 52,498 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Replimune Group during the second quarter worth about $443,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Price Performance

NASDAQ:REPL traded up $0.03 during midday trading on Friday, hitting $14.08. 474,085 shares of the company were exchanged, compared to its average volume of 1,072,794. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The company has a fifty day simple moving average of $11.89 and a 200 day simple moving average of $10.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. Research analysts expect that Replimune Group, Inc. will post -2.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of the company's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company's stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on REPL shares. Roth Capital raised shares of Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. HC Wainwright reissued a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Friday, November 22nd. Roth Mkm started coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a "buy" rating and a $17.00 price objective for the company. BMO Capital Markets boosted their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a research note on Friday, November 22nd. Finally, JPMorgan Chase & Co. raised their price target on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, September 24th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $17.00.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.